How do you get water to float in midair? With a WAND2, of course. But it’s hardly magic. In fact, it’s a scientific device used by scientists to study matter.
ORNL will lead three new DOE-funded projects designed to bring fusion energy to the grid on a rapid timescale.
Creating energy the way the sun and stars do — through nuclear fusion — is one of the grand challenges facing science and technology. What’s easy for the sun and its billions of relatives turns out to be particularly difficult on Earth.
ORNL will team up with six of eight companies that are advancing designs and research and development for fusion power plants with the mission to achieve a pilot-scale demonstration of fusion within a decade.
How did we get from stardust to where we are today? That’s the question NASA scientist Andrew Needham has pondered his entire career.
Scientists at ORNL used neutron scattering to determine whether a specific material’s atomic structure could host a novel state of matter called a spiral spin liquid.
More than 50 current employees and recent retirees from ORNL received Department of Energy Secretary’s Honor Awards from Secretary Jennifer Granholm in January as part of project teams spanning the national laboratory system. The annual awards recognized 21 teams and three individuals for service and contributions to DOE’s mission and to the benefit of the nation.
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
A team led by the U.S. Department of Energy’s Oak Ridge National Laboratory demonstrated the viability of a “quantum entanglement witness” capable of proving the presence of entanglement between magnetic particles, or spins, in a quantum material.
An ORNL-led team comprising researchers from multiple DOE national laboratories is using artificial intelligence and computational screening techniques – in combination with experimental validation – to identify and design five promising drug therapy approaches to target the SARS-CoV-2 virus.